Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-98633, BCMA-TARGETED NEX-T CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Principal Investigator: McCarthy, Philip L

Detection by circulating RNA with OPtimized machine LEarning Technology for Breast Cancer: DROPLET-BC Study

Principal Investigator: Gandhi, Shipra

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release (bb2121-EAP-001)

Principal Investigator: McCarthy, Philip L

9801-CL-0101 A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors

Principal Investigator: Fountzilas, Christos

(S2001) Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Principal Investigator: Fountzilas, Christos

Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)

Principal Investigator: Kukar, Moshim

Acute GVHD Suppression using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)

Principal Investigator: Barth, Matthew J

S1900E, A PHASE II STUDY OF SOTORASIB (AMG 510) IN PARTICIPANTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Principal Investigator: Levine, Ellis G

Transurethral Resection of Bladder Tumor (TURBT): Quality Assurance Database

Principal Investigator: Aly, Ahmed A

S1937,A PHASE III RANDOMIZED TRIAL OF ERIBULIN (NSC #707389) WITH OR WITHOUT GEMCITABINE VERSUS STANDARD OF CARE (PHYSICIAN S CHOICE) FOR TREATMENT OF METASTATIC UROTHELIAL CARCINOMA REFRACTORY TO, OR INELIGIBLE FOR, ANTI PD1/PDL1 THERAPY

Principal Investigator: Levine, Ellis G

Analysis of physical ergonomic risk factors in human-surgical robot shared environment

Principal Investigator: Besharat Shafiei, Somayeh

A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination with Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Principal Investigator: McCarthy, Philip L

PROTOCOL RTOG 1216: RANDOMIZED PHASE II/III TRIAL OF ADJUVANT RADIATION THERAPY WITH CISPLATIN, DOCETAXEL-CETUXIMAB, OR CISPLATIN-ATEZOLIZUMAB IN PATHOLOGIC HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK (NCT 01810913)

Principal Investigator: Singh, Anurag K

INSPIRE: A Multicenter Randomized Controlled Trial integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation

Principal Investigator: Hahn, Theresa E

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Principal Investigator: Wang, Eunice S

Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, nonsquamous, non small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors,…

Principal Investigator: Dy, Grace K

Expanded Access to SurVaxM for Treatment of Patients with Glioblastoma Who Have No Access to Other Comparable or Alternative Therapy or Have Completed Treatment on a non-Randomized Clinical Trial of SurVaxM and May Benefit from Further Treatment

Principal Investigator: Abad, Ajay P

Phase 2 Study of MK-6482 in Participants with Advanced Renal Cell Carcinoma

Principal Investigator: George, Saby

A Phase II Trial of Lamivudine in Combination with Chemoimmunotherapy in Patients with Extensive Stage SCLC

Principal Investigator: Dy, Grace K

A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN, CTEP-SUPPLIED BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN AND…

Principal Investigator: Lele, Shashikant B

Prospective, observational, non-interventional feasibility study of Minimal Residual Disease assessment with CAncer Personalized Profiling by deep sequencing in patients with newly diagnosed peripheral T cell lymphoma.

Principal Investigator: Ghione, Paola

A Single-center Phase I Dose Escalation/Response Trial to Evaluate the Safety, Tolerability, and Anti-tumor Efficacy of Intra-arterial CBL0137 for Patients with Advanced Extremity Melanoma or Sarcoma

Principal Investigator: Skitzki, Joseph J

MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38…

Principal Investigator: Hillengass, Jens

A Phase 3, Open-label, Randomized, Non-Inferiority Trial of Subcutaneous (SC) versus Intravenous (IV) Nivolumab in Advanced, or Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Who Have Received Prior Anti-Angiogenic Therapy

Principal Investigator: George, Saby

Randomized, placebo-controlled, phase II trial examining ustekinumab for prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation

Principal Investigator: Chen, George L